Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has reported positive results from a phase 3 pivotal trial of esaxerenone, a product of the companies prior research collaboration, in patients with diabetic nephropathy.